Skip to main content

Actimmune Disease Interactions

There are 3 disease interactions with Actimmune (interferon gamma-1b).

Major

Interferons (applies to Actimmune) cardiac disease

Major Potential Hazard, High plausibility. Applicable conditions: Congestive Heart Failure, Ischemic Heart Disease, Arrhythmias

Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy. Therapy with interferons should be administered with caution in patients with compromised cardiac function.

References

  1. (2002) "Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories
  2. (2001) "Product Information. Avonex (interferon beta-1a)." Biogen
  3. (2001) "Product Information. Intron A (interferon alfa-2b)." Schering Corporation
  4. (2001) "Product Information. Infergen (interferon alfacon-1)." Amgen
  5. (2001) "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation
  6. (2002) "Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories
  7. (2015) "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation
  8. (2021) "Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp
View all 8 references
Major

Interferons (applies to Actimmune) CNS dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Parkinsonism, Seizures, Psychosis

Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons. Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.

References

  1. (2002) "Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories
  2. (2001) "Product Information. Avonex (interferon beta-1a)." Biogen
  3. (2001) "Product Information. Intron A (interferon alfa-2b)." Schering Corporation
  4. (2001) "Product Information. Infergen (interferon alfacon-1)." Amgen
  5. (2001) "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation
  6. (2015) "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation
  7. (2021) "Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp
View all 7 references
Moderate

Interferons (applies to Actimmune) myelosuppression

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression. Leukopenia is the primary manifestation. Thrombocytopenia and anemia occur less frequently. Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression. Clinical monitoring of hematopoietic function is recommended.

References

  1. (2001) "Product Information. Intron A (interferon alfa-2b)." Schering Corporation
  2. (2001) "Product Information. Infergen (interferon alfacon-1)." Amgen
  3. (2001) "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation
  4. (2015) "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation
  5. (2021) "Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp
View all 5 references

Actimmune drug interactions

There are 186 drug interactions with Actimmune (interferon gamma-1b).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer